Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetically manipulated bacterial toxin as a new generation mucosal adjuvant.

Scandinavian journal of immunology - 1 Mar 2001

Yamamoto M, McGhee J R, Hagiwara Y, Otake S, Kiyono H

Abstract excerpt

Cholera toxin (CT) and heat-labile toxin (LT) of Escherichia coli act as adjuvants for the enhancement of mucosal and serum antibody (Ab) responses to mucosally co-administered protein antigen (Ag). Both LT and CT induce B7-2 expression on antigen-presenting cells (APCs) for subsequent co-stimulatory signalling to CD4+ T cells. CT directly affects CD4+ T cells activated via the TCR-CD3 complex with selective...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adjuvants, Immunologic
Share to Antigen-Presenting Cells
Share to B7-2 Antigen

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cholera Toxin

Share to Enterotoxins

Share to Genetic Engineering

Share to Immunity, Mucosal

Share to Interleukin-4

Source

Identifiers

PMID: 11251876
DOI: 10.1046/j.1365-3083.2001.00883.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetically manipulated bacterial toxin as a new generation mucosal adjuvant.PMID 11251876Read ↗

Non-toxic derivatives of LT as potent adjuvants.Semantic proximity Read ↗

Mucosal vaccines: non toxic derivatives of LT and CT as mucosal adjuvants.Semantic proximity Read ↗

Escherichia coli heat-labile enterotoxin promotes protective Th17 responses against infection by driving innate IL-1 and IL-23 production.Semantic proximity Read ↗

Mucosal immunization of mice using CpG DNA and/or mutants of the heat-labile enterotoxin of Escherichia coli as adjuvants.Semantic proximity Read ↗

Adjuvant activity of a nontoxic mutant of Escherichia coli heat-labile enterotoxin on systemic and mucosal immune responses elicited against a heterologous antigen carried by a live Salmonella enterica serovar Typhimurium vaccine strain.Semantic proximity Read ↗

Mutants in the ADP-ribosyltransferase cleft of cholera toxin lack diarrheagenicity but retain adjuvanticity.Semantic proximity Read ↗

Construction and preclinical evaluation of mmCT, a novel mutant cholera toxin adjuvant that can be efficiently produced in genetically manipulated Vibrio cholerae.Semantic proximity Read ↗

Escherichia coli LTB26 mutant enhances immune responses to rotavirus antigen VP8 in a mouse model.Semantic proximity Read ↗

Cholera Toxin Subunit B as Adjuvant––An Accelerator in Protective Immunity and a Break in AutoimmunitySemantic proximity Read ↗

Mutant Escherichia coli heat-labile enterotoxin [LT(R192G)] enhances protective humoral and cellular immune responses to orally administered inactivated influenza vaccine.Semantic proximity Read ↗

A Novel High-Potency Tetanus Vaccine.Semantic proximity Read ↗

Mutants of the Escherichia coli heat-labile enterotoxin as safe and strong adjuvants for intranasal delivery of vaccines.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.